The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease

被引：0
作者：
Daniel Twohig
Elena Rodriguez-Vieitez
Sigrid B. Sando
Guro Berge
Camilla Lauridsen
Ina Møller
Gøril R. Grøntvedt
Geir Bråthen
Kalicharan Patra
Guojun Bu
Tammie L. S. Benzinger
Celeste M. Karch
Anne Fagan
John C. Morris
Randall J. Bateman
Agneta Nordberg
Linda R. White
Henrietta M. Nielsen
机构：
[1] Stockholm University,Department of Biochemistry and Biophysics
[2] Karolinska Institutet,Department of Neurobiology, Care Sciences and Society
[3] University Hospital of Trondheim,Department of Neurology
[4] Norwegian University of Science and Technology,Department of Neuroscience
[5] Department of Neuroscience,Department of Radiology
[6] Mayo Clinic College of Medicine,Department of Psychiatry
[7] Washington University School of Medicine,Department of Neurology
[8] Washington University School of Medicine,The Aging Research Center
[9] Washington University School of Medicine,undefined
[10] Karolinska University Hospital,undefined
来源：
Acta Neuropathologica Communications | / 6卷
关键词：
Alzheimer’s disease; Mild cognitive impairment; alpha-synuclein; Biomarkers; APOEε4;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Accumulating evidence demonstrating higher cerebrospinal fluid (CSF) α-synuclein (αSyn) levels and αSyn pathology in the brains of Alzheimer’s disease (AD) patients suggests that αSyn is involved in the pathophysiology of AD. To investigate whether αSyn could be related to specific aspects of the pathophysiology present in both sporadic and familial disease, we quantified CSF levels of αSyn and assessed links to various disease parameters in a longitudinally followed cohort (n = 136) including patients with sporadic mild cognitive impairment (MCI) and AD, and in a cross-sectional sample from the Dominantly Inherited Alzheimer’s Network (n = 142) including participants carrying autosomal dominant AD (ADAD) gene mutations and their non-mutation carrying family members.
引用
收藏
相关论文
共 348 条
[1]  
Arai Y(2001)α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation Brain Res 888 287-296
[2]  
Yamazaki M(2015)Inhibition of amyloid-β plaque formation by α-synuclein Nat Med 21 802-807
[3]  
Mori O(2011)Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease Alzheimers Res Ther 3 1-804
[4]  
Muramatsu H(2012)Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 367 795-502
[5]  
Asano G(2015)Effect of Tween-20 on Core biomarkers measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy control individuals J Alzheimer’s Dis 49 493-1231
[6]  
Katayama Y(2016)Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study BMC Neurol BioMed Central 16 180-12
[7]  
Bachhuber T(2014)Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort J Neurol Neurosurg Psychiatry 85 1227-7289
[8]  
Katzmarski N(2010)An overview of APP processing enzymes and products NeuroMolecular Med 12 1-923
[9]  
McCarter JF(2010)Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline J Neurosci 30 7281-780
[10]  
Loreth D(1993)Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families Science 261 921-6851
12345678910